| Unraveling the formation of Tb/Pd films by coupled reduction as targets for heavy ion-beam irradiation
Cerboni, N., Szekér, B., Dressler, R., Wörle, M., Eichler, R., Jung, T. A., … Maugeri, E. A. (2025). Unraveling the formation of Tb/Pd films by coupled reduction as targets for heavy ion-beam irradiation. Journal of Alloys and Compounds, 1010, 176954 (11 pp.). https://doi.org/10.1016/j.jallcom.2024.176954 |
| First-in-human administration of [<sup>161</sup>Tb]Tb-SibuDAB and comparative dosimetry with standard [<sup>177</sup>Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
Chirindel, A., Nicolas, G. P., Westerbergh, F., McDougall, L., Schmid, D. E., Geistlich, S., … Schibli, R. (2025). First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1628-1630. https://doi.org/10.1007/s00259-024-07009-w |
| Preclinical investigation of [<sup>149</sup>Tb]Tb-DOTATATE and [<sup>149</sup>Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy
Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., … Müller, C. (2025). Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1383-1398. https://doi.org/10.1007/s00259-024-07035-8 |
| Alpha Atlas: mapping global production of α-emitting radionuclides for targeted alpha therapy
Tosato, M., Favaretto, C., Kleynhans, J., Burgoyne, A. R., Gestin, J. F., van der Meulen, N. P., … Radchenko, V. (2025). Alpha Atlas: mapping global production of α-emitting radionuclides for targeted alpha therapy. Nuclear Medicine and Biology, 142-143, 108990 (23 pp.). https://doi.org/10.1016/j.nucmedbio.2024.108990 |
| Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form
Wallimann, R. H., Mehta, A., Mapanao, A. K., Köster, U., Kneuer, R., Schindler, P., … Müller, C. (2025). Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1370-1382. https://doi.org/10.1007/s00259-024-07018-9 |
| Comparison of the tolerability of <sup>161</sup>Tb- and <sup>177</sup>Lu-labeled somatostatin analogues in the preclinical setting
Busslinger, S. D., Mapanao, A. K., Kegler, K., Bernhardt, P., Flühmann, F., Fricke, J., … Müller, C. (2024). Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting. European Journal of Nuclear Medicine and Molecular Imaging, 51, 4049-4061. https://doi.org/10.1007/s00259-024-06827-2 |
| Terbium-149 production: a focus on yield and quality improvement towards preclinical application
Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Busslinger, S. D., … van der Meulen, N. P. (2024). Terbium-149 production: a focus on yield and quality improvement towards preclinical application. Scientific Reports, 14(1), 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2 |
| First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
Fricke, J., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., … Wild, D. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging, 51, 2517-2519. https://doi.org/10.1007/s00259-024-06641-w |
| Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours
Gomes, C. V., Mendes, B. M., Paixão, L., Gnesin, S., Müller, C., van der Meulen, N. P., … Lima, T. V. M. (2024). Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours. EJNMMI Physics, 11(1), 61 (14 pp.). https://doi.org/10.1186/s40658-024-00669-5 |
| Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with <sup>161</sup>Tb and <sup>177</sup>Lu: a comparative study
Holzleitner, N., Cwojdzinski, T., Beck, R., Urtz-Urban, N., Hillhouse, C. C., Grundler, P. V., … Günther, T. (2024). Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with 161Tb and 177Lu: a comparative study. Journal of Nuclear Medicine, 65(3), 481-484. https://doi.org/10.2967/jnumed.123.266233 |
| Terbium sisters: current development status and upscaling opportunities
Moiseeva, A. N., Favaretto, C., Talip, Z., Grundler, P. V., & van der Meulen, N. P. (2024). Terbium sisters: current development status and upscaling opportunities. Frontiers in Nuclear Medicine, 4, 1472500 (14 pp.). https://doi.org/10.3389/fnume.2024.1472500 |
| Terbium "Sisters": more than just a "Swiss Army Knife"
Müller, C., & van der Meulen, N. P. (2024). Terbium "Sisters": more than just a "Swiss Army Knife". In V. Prasad (Ed.), Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P. Baum (pp. 225-236). https://doi.org/10.1007/978-3-031-33533-4_23 |
| Development of radionuclides for theragnostic applications at the Paul Scherrer Institut (PSI)
Pautz, A., Eichler, R., & van der Meulen, N. P. (2024). Development of radionuclides for theragnostic applications at the Paul Scherrer Institut (PSI). In A. Shams, K. Al-Athel, I. Tiselj, A. Pautz, & T. Kwiatkowski (Eds.), Lecture Notes in Mechanical Engineering (LNME). Challenges and recent advancements in nuclear energy systems. Proceedings of Saudi international conference on nuclear power engineering (SCOPE) (pp. 39-44). https://doi.org/10.1007/978-3-031-64362-0_5 |
| Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Toyohara, J., Vugts, D., Kiss, O. C., Todde, S., Li, X. G., Liu, Z., … Bourdeau, C. (2024). Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 9, 42 (20 pp.). https://doi.org/10.1186/s41181-024-00268-w |
| A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
Beyer, D., Vaccarin, C., Deupi, X., Mapanao, A. K., Cohrs, S., Sozzi-Guo, F., … Müller, C. (2023). A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. EJNMMI Research, 13(1), 32 (14 pp.). https://doi.org/10.1186/s13550-023-00979-2 |
| Cross-section measurement of thulium radioisotopes with an 18 MeV medical PET cyclotron for an optimized <sup>165</sup>Er production
Dellepiane, G., Casolaro, P., Favaretto, C., Gottstein, A., Grundler, P. V., Mateu, I., … Braccini, S. (2023). Cross-section measurement of thulium radioisotopes with an 18 MeV medical PET cyclotron for an optimized 165Er production. Applied Radiation and Isotopes, 200, 110954 (11 pp.). https://doi.org/10.1016/j.apradiso.2023.110954 |
| <sup>161</sup>Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of <sup>161</sup>Tb into the clinic
Favaretto, C., Grundler, P. V., Talip, Z., Landolt, S., Sepini, L., Köster, U., … van der Meulen, N. P. (2023). 161Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of 161Tb into the clinic. Journal of Nuclear Medicine, 64(7), 1138-1144. https://doi.org/10.2967/jnumed.122.265268 |
| Synthesis and preclinical evaluation of radiolabeled [<sup>103</sup>Ru]BOLD-100
Happl, B., Brandt, M., Balber, T., Benčurová, K., Talip, Z., Voegele, A., … Mindt, T. L. (2023). Synthesis and preclinical evaluation of radiolabeled [103Ru]BOLD-100. Pharmaceutics, 15(11), 2626 (11 pp.). https://doi.org/10.3390/pharmaceutics15112626 |
| Activity measurement of <sup>44</sup>Sc and calibration of activity measurement instruments on production sites and clinics
Juget, F., Durán, T., Nedjadi, Y., Talip, Z., Grundler, P. V., Favaretto, C., … van der Meulen, N. P. (2023). Activity measurement of 44Sc and calibration of activity measurement instruments on production sites and clinics. Molecules, 28(3), 1345 (10 pp.). https://doi.org/10.3390/molecules28031345 |
| Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
Müller, C., van der Meulen, N. P., & Schibli, R. (2023). Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. European Journal of Nuclear Medicine and Molecular Imaging, 50, 3181-3184. https://doi.org/10.1007/s00259-023-06316-y |
